Pelacarsen, Lp(a)HORIZON
Elevated lipoprotein(a) with established cardiovascular disease
Sponsor: Novartis
- N/AEnrollment target
- N/ATrial sites
- N/ACountries
- TBDEst. completion
- N/ARegistry record
About this trial
The first large cardiovascular outcomes test of the lipoprotein(a) hypothesis.
Primary endpoints
- Major adverse cardiovascular events
Latest update
September 2026
Novartis announced Lp(a)HORIZON topline results showing pelacarsen did not meet its primary objective in patients with elevated lipoprotein(a) and established cardiovascular disease. The result reopened the question of whether lowering Lp(a) as a biomarker translates into fewer cardiovascular events, with read-across to every other Lp(a) programme.
SourceTrial information is compiled from public sources and may be out of date. It is not medical advice and is not an offer of enrolment; check the registry entry or speak to a physician before acting on it.